Strides Issues Response To Latest U.S. FDA Complaint About India Drugs
This article was originally published in PharmAsia News
Executive Summary
Strides Arcolab has responded to a U.S. FDA Form-483 about one of its drug-production plants and expects the situation to be resolved in the company's favor, according to CEO Arun Kumar.